相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rufinamide-Loaded Chitosan Nanoparticles in Xyloglucan-Based Thermoresponsive In Situ Gel for Direct Nose to Brain Delivery
Avantika Dalvi et al.
FRONTIERS IN PHARMACOLOGY (2021)
Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene
Aditya Murthy et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals
Bahman Homayun et al.
PHARMACEUTICS (2019)
Chitosan-Based Nanocarriers for Nose to Brain Delivery
Blessing Atim Aderibigbe et al.
APPLIED SCIENCES-BASEL (2019)
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
Muhammad Muzamil Khan et al.
DRUG DELIVERY (2019)
Development and validation of rapid and sensitive LC methods with PDA and fluorescence detection for determination of piribedil in rat plasma and brain tissues and their pharmacokinetic application
Chandra Teja Uppuluri et al.
BIOMEDICAL CHROMATOGRAPHY (2018)
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting
Fabio Sonvico et al.
PHARMACEUTICS (2018)
Evaluation of intranasal delivery route of drug administration for brain targeting
Franciska Erdo et al.
BRAIN RESEARCH BULLETIN (2018)
Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles
Ejaj Ahmad et al.
NANOSCALE (2017)
Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review
Giovanna Rassu et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2016)
Non-motor symptoms in Parkinson's disease
Ronald F. Pfeiffer
PARKINSONISM & RELATED DISORDERS (2016)
Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization
P. R. Ravi et al.
DRUG DELIVERY (2015)
Quercetin-Loaded Lecithin/Chitosan Nanoparticles for Functional Food Applications
Marthyna P. Souza et al.
FOOD AND BIOPROCESS TECHNOLOGY (2014)
Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil
Stephane Thobois et al.
BRAIN (2013)
Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting
Chandrakantsing Vijaysing Pardeshi et al.
EXPERT OPINION ON DRUG DELIVERY (2013)
Intranasal delivery of biologics to the central nervous system
Jeffrey J. Lochhead et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Lecithin/chitosan nanoparticles for transdermal delivery of melatonin
Anita Hafner et al.
JOURNAL OF MICROENCAPSULATION (2011)
Cell-Penetrating Peptide-Modified Block Copolymer Micelles Promote Direct Brain Delivery via Intranasal Administration
Takanori Kanazawa et al.
PHARMACEUTICAL RESEARCH (2011)
Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Aravind Mittur
CURRENT DRUG THERAPY (2011)
Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations
Shyeilla V. Dhuria et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease
Mark J. Millan
PHARMACOLOGY & THERAPEUTICS (2010)
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease
Leah R. Hanson et al.
BMC NEUROSCIENCE (2008)
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study
Olivier Rascol et al.
MOVEMENT DISORDERS (2006)
Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction
F. Sonvico et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor.: II.: Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor
A Newman-Tancredi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor.: III.: Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes
A Newman-Tancredi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes
MJ Millan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
D Deleu et al.
CLINICAL PHARMACOKINETICS (2002)
Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset
LA Smith et al.
CLINICAL NEUROPHARMACOLOGY (2000)
分享论文
